Current Research and Development Projects and Products

Skin pigmentation control and melanoma chemotherapy are serious goals for people from all walks of life. Affected individuals suffering from occupational or recreational exposure to sunlight, including sun-tanning, or experiencing drug-induced hyperpigmentation, look to the cosmetic industry for help, mainly because the pharmaceutical industry has not championed scientifically proven remedies. Similarly, melanoma-targeted drugs are largely ineffective, leaving chemotherapy as a last and usually futile attempt to treat advanced-stage melanoma.

Hermay Labs has developed a series of compounds representing a new opportunity to modulate skin hyperpigmentation and inhibit melanoma growth at the biomolecular level.  Hermay Labs is seeking partners and collaborators, and is offering investors early-stage opportunities to promote this technology.

Statistics reveal that 1 in 2 men and 1 in 3 women have cancer in their lifetime; 1 in 4 men and 1 in 5 women will die from these malignant diseases. A novel emerging approach to fighting cancer is a technology called Proteolysis Targeting Chimeras or PROTACs. Unlike the competitive and occupancy-driven process of traditional inhibitors, PROTACs molecules are catalytic in their mode of action, where they promote target protein degradation at low exposure concentrations. PROTACs have the potential to degrade the target pathogenic protein and complete shunt-related signalling pathways, a process not achieved by traditional therapies (inhibitor/activator). As a promising new technology, PROTACs have gained significant attention from academia and the pharmaceutical and biotechnology industry. Although important advances have been made with the PROTAC technology, there are many clinical development challenges. One critical challenge is to increase the clinical success potential while reducing chemoresistance. For example, E3 ligases dictate ubiquitination/removal of the target molecules, and current PROTAC drug candidates target only a single E3 ubiquitin ligase. This has the potential for the drug to fail, as the targeted E3 ubiquitin ligase may not be present in every cancer cell and tissue type, and the targeted E3 ubiquitin ligase may become mutated during acquired drug resistance. Hermay Labs Corporation has developed a series of lead compounds that can simultaneously bind to three different homologous E3 ubiquitin ligases, thereby largely by-passing effective acquired resistance. We believe this will revolutionize the paradigm of PROTAC development and design because our platform will increase efficacy and decrease potential drug resistance.

The global water and wastewater treatment market is expected to reach $211.3 billion by 2025, at a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2019 to 2025. At Hermay Labs, we intend to improve water treatments by developing innovative, affordable and sustainable water treatment materials.

Hermay Labs and its European collaborator have developed a series of water filtering materials that efficiently and economically treat water: a SuperFilter system that filters natural water to provide drinkable (potable) water; a FirstFilter system to remove the environmental pollutants from industrial wastewater; and a FineFilter system which can remove heavy metal pollutants.